Weight Changes and Treatments After Stopping Semaglutide or Tirzepatide in Medical Care

Dr. Hamlet Gasoyan reported receiving grant funding from the National Cancer Institute outside the submitted work. Dr. Christopher B. Boyer reports consulting fees from Janssen Pharmaceuticals outside the submitted work. Dr. W. Scott Butsch is currently employed by Novo Nordisk A/S; he also reported advisory board fees from Eli Lilly, Boehringer Ingelheim and Abbott and research funding from Eli Lilly and Co outside the submitted work. Dr. Ali Aminian reported receiving research grants from Amgen, Ethicon and Medtronic outside the submitted work. He serves as a consultant for Amylyx, Eli Lilly, Ethicon and Medtronic. Dr. Marcio L. Griebeler reported research funding from Novo Nordisk A/S outside the submitted work. Dr. Michael B. Rothberg reported receiving consulting fees from the Blue Cross Blue Shield Association outside the submitted work. The other authors declare no conflicts of interest.